Navigation Links
Martek Announces Second Quarter 2008 Financial Results
Date:6/4/2008

ities 10,748 18,827

Stockholders' equity 566,448 531,727

Total liabilities and stockholders' equity $620,415 $596,695

Unaudited Condensed Consolidated Cash Flow Data

Six months ended

April 30,

2008 2007

Operating activities:

Net income $17,871 $7,619

Non-cash items 24,464 18,067

Changes in operating assets and liabilities, net (3,579) (17,896)

Net cash provided by operating activities 38,756 7,790

Investing activities:

(Purchase) sale of investments and marketable

securities, net (10,850) 6,850

Expenditures for property, plant and equipment (3,576) (3,059)

Repurchase of sale-leaseback equipment - (3,910)

Capitalization of intangible assets (2,165) (3,929)

Net cash used in investing activities (16,591) (4,048)

Financing activities:

Repayments of notes payable and other

long-term obligations, net (426) (505)

Repayments under revolving credit facility, net - (5,000)

Proceeds from stock option exercises and

other, net 5,944 1,903

Net cash provided by (used in) financing

activities 5,518 (3,602)

Net change in cash, cash equivalents 27,683 140

Cash and cash equivalents, beginning of period 16,973 15,578

Cash and cash equivalents, end of period
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Martek to Announce Third Quarter 2007 Results on September 5, 2007
2. Martek to Present at Upcoming UBS Conference
3. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
4. Martek Announces Settlement of OmegaTech Milestone Litigation
5. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
6. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
7. Martek to Present at Upcoming ThinkEquity Partners Conference
8. Martek Announces Fourth Quarter and FY 2007 Financial Results
9. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
10. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... BOSTON, MA (PRWEB) March 03, 2015 ... Print Supply Chain, today announced the expansion of its ... quality, color-matched print to 850 the world’s largest cities ... Supply Chain extends to 137 countries providing global enterprises ... the print procurement process from online order to real-world ...
(Date:3/3/2015)... 2015  Thingee Corporation, a software development company for ... entitled, "Technology Adoption: Making Reps, Lives Easier" during the ... Technology ,  in Deerfield Beach, Florida ... Audiences looking to learn how technology can help them ... in the audience for the Thingee presentation. ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and ... 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy ... Santa Ana division (the "Bankruptcy Court") on ... to be jointly administered. The Company will evaluate ... for all or substantially all of its assets to a ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... NATICK, Mass., Nov. 9, 2010 Boston Scientific Corporation ... implantation of its Vercise™ Deep Brain Stimulation (DBS) System ... a multi-center, prospective trial designed to examine the improvement ... with the Vercise DBS System for the treatment of ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it has submitted a full proposal to ... under BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense . ...
... Professor Andre Geim, who along with his colleague Professor ... the world,s thinnest material, has now modified it ... to Teflon. Fluorographene is fully-fluorinated graphene and is ... including chemical inertness and thermal stability. The ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Graphene gets a Teflon makeover 2Graphene gets a Teflon makeover 3
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... to a report issued last week by UNAIDS, access ... worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and ... Center for Infectious Disease Research in Zambia (CIDRZ) warns ... dying of cervical cancer unless they have access to ...
... at The University of Manchester have developed a new x-ray ... and human cancers more effectively. Professor Robert Cernik and ... colour 3D X-ray system that allows material at each point ... work is reported in the latest issue of The Journal ...
... for commercial genetic testing is on the rise and ... (MGH) physician. In the December issue of Obstetrics ... testing is poorly regulated and may present potential pitfalls ... that are being offered have no proven clinical validity ...
Cached Biology News:Women with AIDS face cervical cancer threat 2New X-ray technique targets terrorists and tumors 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Fibulin-2 (D-15)...
Biology Products: